Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype.
Thompson
Alexander J
AJ
Muir
Andrew J
AJ
Sulkowski
Mark S
MS
Patel
Keyur
K
Tillmann
Hans L
HL
Clark
Paul J
PJ
Naggie
Susanna
S
Fellay
Jacques
J
Ge
Dongliang
D
McCarthy
Jeanette J
JJ
Goldstein
David B
DB
McHutchison
John G
JG
D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D000095022:Interferon Lambda
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a